SCL Healthcare Secures U.S. Patent for Genetic Test Predicting Metabolic Syndrome Risk

SCL Healthcare has successfully secured a U.S. patent for a novel genetic testing technology designed to predict an individual’s risk of elevated blood ceramide levels—a biological substance widely cited as a primary driver of metabolic syndrome and Type 2 diabetes.

The company announced on June 18 that its proprietary genetic marker technology, which enables the early prediction, diagnosis, and stratification of high-risk groups for elevated ceramide expression, has been officially registered with the U.S. Patent and Trademark Office (USPTO).

While metabolic syndrome and Type 2 diabetes have long been understood to stem primarily from insulin resistance, recent clinical research has increasingly spotlighted ceramide. A bioactive lipid, ceramide has emerged as a key molecule that actively interferes with insulin signaling pathways, significantly escalating the risk of metabolic and cardiovascular complications. The excessive accumulation of these lipids in the bloodstream is heavily correlated with the development of various chronic conditions.

Early Intervention Through Bioactive Lipids

SCL Healthcare’s newly patented method utilizes 12 single-nucleotide polymorphism (SNP) genetic markers identified through a comprehensive genome-wide association study (GWAS). By analyzing these specific genetic variants, the technology can determine a patient's susceptibility to metabolic syndrome based purely on genetic data before the condition fully manifests. Furthermore, the platform offers a more refined diagnostic breakdown by analyzing distinct structural subtypes of ceramide.

The company expects the diagnostic tool to assist healthcare providers in establishing highly personalized preventative and management strategies tailored to an individual’s unique genetic profile. SCL Healthcare emphasized that securing a patent in the United States is a major milestone, validating the technology's originality and sophistication within the world's largest biohealth market. The patent is poised to strengthen the company's competitive edge in preventative medicine globally, particularly as the prevalence of metabolic syndrome continues to rise due to shifting dietary patterns and increasing obesity rates.

Commercialization and Global Expansion

Moving forward, the technology is slated for deployment across multiple clinical and commercial sectors. These include the manufacturing of early-prediction diagnostic kits, integration into risk-assessment services at major health screening centers, and utilization as companion diagnostic biomarkers to screen specific genotypes during pharmaceutical clinical trials.

"We are focused on commercializing this high-quality metabolic disease prediction service for clinical environments as rapidly as possible," an official from SCL Healthcare stated. "We will continue to expand our pipeline of precision medicine-based diagnostic products."

SCL Healthcare operates as a subsidiary of SCL Science, a data-driven precision medicine firm. In tandem with its metabolic research, the company leverages single-cell big data to pioneer cutting-edge diagnostic tools, including platelet-based multi-cancer early detection platforms and companion homologous recombination deficiency (HRD) testing technologies for ovarian cancer.